Cargando…

“Cytokine storm”, not only in COVID-19 patients. Mini-review

Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient’s death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently ment...

Descripción completa

Detalles Bibliográficos
Autor principal: Lukan, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Immunological Societies. Published by Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524442/
https://www.ncbi.nlm.nih.gov/pubmed/33007369
http://dx.doi.org/10.1016/j.imlet.2020.09.007
_version_ 1783588551819001856
author Lukan, Norbert
author_facet Lukan, Norbert
author_sort Lukan, Norbert
collection PubMed
description Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient’s death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs. Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients. Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm. Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches.
format Online
Article
Text
id pubmed-7524442
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Federation of Immunological Societies. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75244422020-09-30 “Cytokine storm”, not only in COVID-19 patients. Mini-review Lukan, Norbert Immunol Lett Article Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient’s death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs. Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients. Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm. Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches. European Federation of Immunological Societies. Published by Elsevier B.V. 2020-12 2020-09-29 /pmc/articles/PMC7524442/ /pubmed/33007369 http://dx.doi.org/10.1016/j.imlet.2020.09.007 Text en © 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lukan, Norbert
“Cytokine storm”, not only in COVID-19 patients. Mini-review
title “Cytokine storm”, not only in COVID-19 patients. Mini-review
title_full “Cytokine storm”, not only in COVID-19 patients. Mini-review
title_fullStr “Cytokine storm”, not only in COVID-19 patients. Mini-review
title_full_unstemmed “Cytokine storm”, not only in COVID-19 patients. Mini-review
title_short “Cytokine storm”, not only in COVID-19 patients. Mini-review
title_sort “cytokine storm”, not only in covid-19 patients. mini-review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524442/
https://www.ncbi.nlm.nih.gov/pubmed/33007369
http://dx.doi.org/10.1016/j.imlet.2020.09.007
work_keys_str_mv AT lukannorbert cytokinestormnotonlyincovid19patientsminireview